The National Institute for Health and Care Excellence

Patients to get new medicines up to six months sooner

A new aligned pathway between the Medicines and Healthcare products Regulatory Agency (MHRA) and NICE, along with an improved advice service, will help bring medicines to patients faster and give ...
The National Institute for Health and Care Excellence

500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause

A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable. Fezolinetant (also called Veoza and made by Astellas ...
The National Institute for Health and Care Excellence

Saving babies' hearing: how a world-first rapid genetic test is transforming neonatal care

Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 ...
National Institute for Health and Care Excellence

Suspected sepsis: recognition, diagnosis and early management

This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 TA878 29 March 2023 26 February 2026 ...
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...
National Institute for Health and Care Excellence

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...
National Institute for Health and Care Excellence

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues

We have moved interventional procedures guidance 666 to become HealthTech guidance 535. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment ...
National Institute for Health and Care Excellence

Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma

Isatuximab, plus pomalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults who have had ...
National Institute for Health and Care Excellence

Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment

We have moved health technology evaluation 12 to become HealthTech guidance 696. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme ...